AI assistant
Fulgent Genetics, Inc. — Director's Dealing 2024
Dec 4, 2024
32553_dirs_2024-12-04_b60b2b51-f3b7-465f-ba2e-46a70860ffeb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Fulgent Genetics, Inc. (FLGT)
CIK: 0001674930
Period of Report: 2024-12-03
Reporting Person: Gao Hanlin (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-03 | Common Stock | S | 1373 | $19.4999 | Disposed | 919469 | Direct |
Footnotes
F1: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.
F2: The shares were sold in multiple transactions at prices ranging from $19.46 to $19.58, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.